Share
13,276 Posts.
lightbulb Created with Sketch. 1414
clock Created with Sketch. 13/08/24
00:04
Share
Originally posted by itsagas:
↑
The Bottom LineThe most important thing to take away is that analysts cut their earnings per share estimates, expecting a clear decline in business conditions. While analysts did downgrade their revenue estimates, these forecasts still imply revenues will perform better than the wider market. We're also surprised to see that the price target went unchanged. Still, deteriorating business conditions (assuming accurate forecasts!) can be a leading indicator for the stock price, so we wouldn't blame investors for being more cautious on Sarepta Therapeutics after the downgrade.So things certainly aren't looking great, and you should also know that we've spotted some potential warning signs with Sarepta Therapeutics, including concerns around earnings quality
Expand
Gone from a high of $173 today to a low of $125
